Evax­ion teas­es 67% re­sponse rate in PhI metasta­t­ic melanoma tri­al

Evax­ion Biotech said eight of 12 pa­tients with metasta­t­ic melanoma who re­ceived a com­bi­na­tion of the lead can­di­date and an un­named check­point in­hibitor had a pos­i­tive re­sponse in a Phase I tri­al, in a sneak peak of clin­i­cal da­ta set to be pre­sent­ed at AS­CO next week.

The Dan­ish biotech is de­vel­op­ing EVX-01, a per­son­al­ized can­cer im­munother­a­py that builds off its AI plat­form, which iden­ti­fies neoanti­gens for each pa­tient.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER